The Evolution of CAR-T in R/R DLBCL: Therapeutic Considerations for Second-Line Management

Patrick Reagan, MD*, an expert malignant hematologist from Strong Memorial Hospital, University of Rochester Medical Center, reviews the evolution and therapeutic role of Chimeric Antigen Receptor T-cell (CAR-T) therapy in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), highlighting its shift from third line setting to a preferred second-line (2L) treatment. Topics include a CAR-T mechanistic deep dive, its emerging use alongside other 2L options such as bispecific antibodies, when to prescribe CAR-T within the treatment algorithm and best practices for CAR-T implementation. In this video, Dr Reagen emphasizes that every eligible patient deserves a referral for CAR-T therapy and feels empowered to make an informed choice.

*Paid consultant for Kite Pharma.